CN113797142A - 一种薰衣草乳香黑曜精华液配方及其制备方法 - Google Patents
一种薰衣草乳香黑曜精华液配方及其制备方法 Download PDFInfo
- Publication number
- CN113797142A CN113797142A CN202111177428.XA CN202111177428A CN113797142A CN 113797142 A CN113797142 A CN 113797142A CN 202111177428 A CN202111177428 A CN 202111177428A CN 113797142 A CN113797142 A CN 113797142A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- lavender
- oil
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000178870 Lavandula angustifolia Species 0.000 title claims abstract description 36
- 235000010663 Lavandula angustifolia Nutrition 0.000 title claims abstract description 36
- 239000004863 Frankincense Substances 0.000 title claims abstract description 30
- 239000001102 lavandula vera Substances 0.000 title claims abstract description 29
- 235000018219 lavender Nutrition 0.000 title claims abstract description 29
- 240000007551 Boswellia serrata Species 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000005332 obsidian Substances 0.000 title claims abstract description 22
- 235000003717 Boswellia sacra Nutrition 0.000 title claims abstract description 17
- 235000012035 Boswellia serrata Nutrition 0.000 title claims abstract description 17
- 238000009472 formulation Methods 0.000 title description 3
- 239000000284 extract Substances 0.000 claims abstract description 56
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 48
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 30
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 30
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000003921 oil Substances 0.000 claims abstract description 18
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 16
- YTKGAYFHUZTLCI-UHFFFAOYSA-N 3-hydroxy-2-iminopyrimidin-4-amine Chemical compound NC1=CC=NC(=N)N1O YTKGAYFHUZTLCI-UHFFFAOYSA-N 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000018062 Boswellia Nutrition 0.000 claims abstract description 11
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims abstract description 11
- 244000293846 Polygonatum multiflorum Species 0.000 claims abstract description 11
- 235000004506 Polygonatum multiflorum Nutrition 0.000 claims abstract description 11
- 229960005305 adenosine Drugs 0.000 claims abstract description 11
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims abstract description 10
- 229940015975 1,2-hexanediol Drugs 0.000 claims abstract description 10
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940035437 1,3-propanediol Drugs 0.000 claims abstract description 10
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 10
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 10
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 10
- 239000004359 castor oil Substances 0.000 claims abstract description 10
- 235000019438 castor oil Nutrition 0.000 claims abstract description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 10
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 10
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims abstract description 10
- 229930003799 tocopherol Natural products 0.000 claims abstract description 10
- 229960001295 tocopherol Drugs 0.000 claims abstract description 10
- 239000011732 tocopherol Substances 0.000 claims abstract description 10
- 235000010384 tocopherol Nutrition 0.000 claims abstract description 10
- 239000011709 vitamin E Substances 0.000 claims abstract description 10
- 229940046009 vitamin E Drugs 0.000 claims abstract description 10
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 10
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 10
- KOGFZZYPPGQZFZ-QVAPDBTGSA-N (2s,3r,4s,5r)-2-(2-hydroxypropyl)oxane-3,4,5-triol Chemical compound CC(O)C[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O KOGFZZYPPGQZFZ-QVAPDBTGSA-N 0.000 claims abstract description 8
- GHBFNMLVSPCDGN-UHFFFAOYSA-N caprylic acid monoglyceride Natural products CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000006046 creatine Substances 0.000 claims abstract description 8
- 229960003624 creatine Drugs 0.000 claims abstract description 8
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 claims abstract description 7
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 7
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 7
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229940108925 copper gluconate Drugs 0.000 claims abstract description 7
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000004222 ferrous gluconate Substances 0.000 claims abstract description 7
- 235000013924 ferrous gluconate Nutrition 0.000 claims abstract description 7
- 229960001645 ferrous gluconate Drugs 0.000 claims abstract description 7
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims abstract description 7
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 7
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 7
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 7
- 239000004227 calcium gluconate Substances 0.000 claims abstract description 4
- 229960004494 calcium gluconate Drugs 0.000 claims abstract description 4
- 235000013927 calcium gluconate Nutrition 0.000 claims abstract description 4
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims abstract description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims description 24
- 239000000047 product Substances 0.000 claims description 16
- 244000286838 Eclipta prostrata Species 0.000 claims description 15
- 241000717739 Boswellia sacra Species 0.000 claims description 13
- 240000004371 Panax ginseng Species 0.000 claims description 12
- 235000008434 ginseng Nutrition 0.000 claims description 12
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims description 12
- 241001289529 Fallopia multiflora Species 0.000 claims description 10
- 244000237330 gutta percha tree Species 0.000 claims description 10
- 244000234609 Portulaca oleracea Species 0.000 claims description 9
- 235000001855 Portulaca oleracea Nutrition 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 7
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 6
- 241001288870 Angelica polymorpha Species 0.000 claims description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 6
- 235000002789 Panax ginseng Nutrition 0.000 claims description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 6
- 241000405911 Rehmannia glutinosa Species 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- -1 caprylyl hydroxamic Chemical compound 0.000 claims description 6
- 239000010949 copper Substances 0.000 claims description 6
- 229910052802 copper Inorganic materials 0.000 claims description 6
- 230000001804 emulsifying effect Effects 0.000 claims description 6
- 229940087068 glyceryl caprylate Drugs 0.000 claims description 6
- 229960005323 phenoxyethanol Drugs 0.000 claims description 6
- 229910001220 stainless steel Inorganic materials 0.000 claims description 6
- 239000010935 stainless steel Substances 0.000 claims description 6
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims description 3
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 3
- 241000382455 Angelica sinensis Species 0.000 claims description 3
- 241000628997 Flos Species 0.000 claims description 3
- 241000756042 Polygonatum Species 0.000 claims description 3
- 238000007599 discharging Methods 0.000 claims description 3
- 229940100524 ethylhexylglycerin Drugs 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000002203 pretreatment Methods 0.000 claims description 3
- 229960004063 propylene glycol Drugs 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 239000011265 semifinished product Substances 0.000 claims description 3
- 210000004209 hair Anatomy 0.000 abstract description 33
- 201000004384 Alopecia Diseases 0.000 abstract description 24
- 231100000360 alopecia Toxicity 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 15
- 230000003779 hair growth Effects 0.000 abstract description 9
- 230000001575 pathological effect Effects 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 230000003646 hair health Effects 0.000 abstract description 3
- 241001608538 Boswellia Species 0.000 abstract 1
- 210000003128 head Anatomy 0.000 description 9
- 241000219470 Mirabilis Species 0.000 description 6
- 230000003676 hair loss Effects 0.000 description 6
- 210000004761 scalp Anatomy 0.000 description 6
- 208000024963 hair loss Diseases 0.000 description 5
- 230000003712 anti-aging effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002633 protecting effect Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007952 growth promoter Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000009429 Ginkgo biloba extract Substances 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000003778 catagen phase Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000008266 hair spray Substances 0.000 description 2
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- DDADCBXAKYGDEH-UHFFFAOYSA-N 2-(3-hydroxypropyl)oxane-2,3,4-triol Chemical compound OCCCC1(O)OCCC(O)C1O DDADCBXAKYGDEH-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- 239000005749 Copper compound Substances 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710132031 Mantle protein Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001880 copper compounds Chemical class 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002549 cytobiological effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000003803 hair density Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000013521 mastic Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 210000004918 root sheath Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940124024 weight reducing agent Drugs 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Abstract
本发明公开了一种薰衣草乳香黑曜精华液配方及其制备方法，由以下原料配比组成：水10‑30份、丙二醇5‑8份、乙醇4‑8份、丁二醇3‑7份、甘油2‑4份、乙氧基二甘醇2‑7份、肌酸1‑2份、PEG‑40氢化蓖麻油0.5‑2份、1,3‑丙二醇2‑5份、乳香(BOSWELLIACARTERII)油3‑7份、薰衣草(LAVANDULA ANGUSTIFOLIA)油3‑6份、1,2‑己二醇2‑7份、二氨基嘧啶氧化物1‑3份、葡糖酸锌0.5‑0.8份、葡糖酸钙0.1‑0.3份、葡糖酸铜0.2‑0.4份、葡糖酸亚铁0.3‑0.6份、羟丙基四氢吡喃三醇2‑4份、腺苷3‑6份、银杏(GINKGO BILOBA)叶提取物1‑3份、甘油辛酸酯2‑3份、生育酚(维生素E)1‑4份、多花黄精(POLYGONATUMMULTIFLORUM)根茎/根提取物2‑5份，可改善脂溢性脱发、产后脱发、等病理性脱发以及病理性白发，有促进毛发生长和促进毛发健康的作用。
Description
技术领域
本发明涉及生活用品领域，具体是一种薰衣草乳香黑曜精华液配方及其制备方法。
背景技术
脱发是指头发脱落的现象。正常脱落的头发都是处于退行期及休止期的毛发，由于进入退行期与新进入生长期的毛发不断处于动态平衡，故能维持正常数量的头发。病理性脱发是指头发异常或过度的脱落，其原因很多。
随着现代社会生活节奏越来越快，竞争日益激烈，脱发的人数也呈上升趋势，且出现年轻化的迹象。脱发正成为越来越多现代人的烦恼。很多人自行盲目购买生发水、生发产品，不仅无效反而带来副作用，而有些人却不知该去何处就诊。其实脱发有生理性和病理性之分。正常人的头发每天脱落30～100根，与每天新生的头发基本相等，处于一种动态平衡的代谢之中。假如每天脱发超过100根，而且持续时间比较长，则是病理性脱发。
快速有效治疗脱发问题是当下亟需要解决的问题。
发明内容
本发明的目的在于提供一种薰衣草乳香黑曜精华液配方及其制备方法，以解决上述背景技术中提出的问题。
为实现上述目的，本发明提供如下技术方案：
一种薰衣草乳香黑曜精华液配方及其制备方法，由以下原料配比组成：水10-30份、丙二醇5-8份、乙醇4-8份、丁二醇3-7份、甘油2-4份、乙氧基二甘醇2-7份、肌酸1-2份、PEG-40氢化蓖麻油0.5-2份、1,3-丙二醇2-5份、乳香(BOSWELLIA CARTERII)油3-7份、薰衣草(LAVANDULA ANGUSTIFOLIA)油3-6份、1,2-己二醇2-7份、二氨基嘧啶氧化物1-3份、葡糖酸锌0.5-0.8份、葡糖酸钙0.1-0.3份、葡糖酸铜0.2-0.4份、葡糖酸亚铁0.3-0.6份、羟丙基四氢吡喃三醇2-4份、腺苷3-6份、银杏(GINKGO BILOBA)叶提取物1-3份、甘油辛酸酯2-3份、生育酚(维生素E)1-4份、多花黄精(POLYGONATUM MULTIFLORUM)根茎/根提取物2-5份、熟地黄(REHMANNIA GLUTINOSA)提取物2-5份、人参(PANAX GINSENG)根提取物6-7份、杜仲(EUCOMMIA ULMOIDES)提取物5-8份、何首乌(POLYGONUM MULTIFLORUM)根提取物3-6份、马齿苋(PORTULACA OLERACEA)提取物4-8份、当归(ANGELICA POLYMORPHA SINENSIS)根提取物2-8份、鳢肠(ECLIPTA PROSTRATA)提取物4-8份、三肽-1铜1.5-2份、二甲砜3-7份、辛酰羟肟酸2-9份、苯氧乙醇1-5份和乙基己基甘油3-6份。
作为本发明进一步的方案：其制备方法步骤如下：
步骤一：前期处理：将PEG-40氢化蓖麻油、生育酚(维生素E)、甘油辛酸酯、乳香(BOSWELLIA CARTERII)油、辛酰羟肟酸、1,2-己二醇和1,3-丙二醇置于不锈钢容器中在水浴锅上加热至45-50℃，搅拌至溶解均匀备用；
步骤二：将二氨基嘧啶氧化物和丙二醇置于不锈钢容器中在水浴锅上加热至70-80℃，搅拌至溶解均匀备用；
步骤三：将水、乙醇和腺苷投入乳化锅，加热至65-70℃，搅拌70-80转/分,搅拌10-15分钟，直至分散均匀；
步骤四：乳化锅保温至65℃-70℃，加入甘油、肌酸、乙氧基二甘醇以及预先溶解好的二氨基嘧啶氧化物、丙二醇，搅拌70-80转/分，搅拌10-15分钟，直至搅拌均匀；
步骤五：降温至50-55℃，加入预先溶解好的PEG-40氢化蓖麻油、生育酚(维生素E)、甘油辛酸酯、乳香(BOSWELLIA CARTERII)油和薰衣草(LAVANDULA ANGUSTIFOLIA)油，搅拌70-80转/分,搅拌10-15分钟，直至分散均匀；
步骤六：降温至40-45℃，加入辛酰羟肟酸、1,2-己二醇和1,3-丙二醇、丁二醇、马齿苋(PORTULACA OLERACEA)提取物、葡糖酸锌、鳢肠(ECLIPTA PROSTRATA)提取物、丙二醇、苯氧乙醇、乙基己基甘油、羟丙基四氢吡喃三醇、二甲砜、当归(ANGELICA POLYMORPHASINENSIS)根提取物、何首乌(POLYGONUM MULTIFLORUM)根提取物、人参(PANAX GINSENG)根提取物、银杏(GINKGO BILOBA)叶提取物、多花黄精(POLYGONATUM MULTIFLORUM)根茎/根提取物、熟地黄(REHMANNIA GLUTINOSA)提取物、红花(CARTHAMUS TINCTORIUS)花提取物、杜仲(EUCOMMIA ULMOIDES)叶提取物、葡糖酸铜、葡糖酸亚铁，搅拌70-80转/分,搅拌10-15分钟，直至分散均匀；
步骤七：低于35℃停止搅拌；
步骤八：检验，出料；
步骤九：半成品检验；
步骤十：检验合格后，灌装；
步骤十一：包装；
步骤十二：成品检验，合格品入库。
与现有技术相比，本发明的有益效果是：
可改善脂溢性脱发、产后脱发、等病理性脱发以及病理性白发，有促进毛发生长和促进毛发健康的作用。
附图说明
图1为薰衣草乳香黑曜精华液配方及其制备方法中唐先生4.29号头顶照片图。
图2为薰衣草乳香黑曜精华液配方及其制备方法中唐先生6.28号头顶照片图。
图3为薰衣草乳香黑曜精华液配方及其制备方法中唐先生9.1号头顶照片图。
图4为薰衣草乳香黑曜精华液配方及其制备方法中唐先生4.29号右额角照片图。
图5为薰衣草乳香黑曜精华液配方及其制备方法中唐先生6.28号右额角照片图。
图6为薰衣草乳香黑曜精华液配方及其制备方法中唐先生9.1号右额角照片图。
图7为薰衣草乳香黑曜精华液配方及其制备方法中乐先生8.23号头顶照片图。
图8为薰衣草乳香黑曜精华液配方及其制备方法中乐先生10.12号头顶照片图。
图9为薰衣草乳香黑曜精华液配方及其制备方法中乐先生8.23号左额角照片图。
图10为薰衣草乳香黑曜精华液配方及其制备方法中乐先生10.12号左额角照片图。
图11为薰衣草乳香黑曜精华液配方及其制备方法中乐先生8.23号右额角照片图。
图12为薰衣草乳香黑曜精华液配方及其制备方法中乐先生10.12号右额角照片图。
具体实施方式
下面将结合本发明实施例中的附图，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
请参阅图1～12，本发明实施例中，一种薰衣草乳香黑曜精华液配方及其制备方法，由以下原料配比组成：水10-30份、丙二醇5-8份、乙醇4-8份、丁二醇3-7份、甘油2-4份、乙氧基二甘醇2-7份、肌酸1-2份、PEG-40氢化蓖麻油0.5-2份、1,3-丙二醇2-5份、乳香(BOSWELLIA CARTERII)油3-7份、薰衣草(LAVANDULA ANGUSTIFOLIA)油3-6份、1,2-己二醇2-7份、二氨基嘧啶氧化物1-3份、葡糖酸锌0.5-0.8份、葡糖酸钙0.1-0.3份、葡糖酸铜0.2-0.4份、葡糖酸亚铁0.3-0.6份、羟丙基四氢吡喃三醇2-4份、腺苷3-6份、银杏(GINKGOBILOBA)叶提取物1-3份、甘油辛酸酯2-3份、生育酚(维生素E)1-4份、多花黄精(POLYGONATUM MULTIFLORUM)根茎/根提取物2-5份、熟地黄(REHMANNIA GLUTINOSA)提取物2-5份、人参(PANAX GINSENG)根提取物6-7份、杜仲(EUCOMMIA ULMOIDES)提取物5-8份、何首乌(POLYGONUM MULTIFLORUM)根提取物3-6份、马齿苋(PORTULACA OLERACEA)提取物4-8份、当归(ANGELICA POLYMORPHA SINENSIS)根提取物2-8份、鳢肠(ECLIPTA PROSTRATA)提取物4-8份、三肽-1铜1.5-2份、二甲砜3-7份、辛酰羟肟酸2-9份、苯氧乙醇1-5份和乙基己基甘油3-6份；
其制备方法步骤如下：
步骤一：前期处理：将PEG-40氢化蓖麻油、生育酚(维生素E)、甘油辛酸酯、乳香(BOSWELLIA CARTERII)油、辛酰羟肟酸、1,2-己二醇和1,3-丙二醇置于不锈钢容器中在水浴锅上加热至45-50℃，搅拌至溶解均匀备用；
步骤二：将二氨基嘧啶氧化物和丙二醇置于不锈钢容器中在水浴锅上加热至70-80℃，搅拌至溶解均匀备用；
步骤三：将水、乙醇和腺苷投入乳化锅，加热至65-70℃，搅拌70-80转/分,搅拌10-15分钟，直至分散均匀；
步骤四：乳化锅保温至65℃-70℃，加入甘油、肌酸、乙氧基二甘醇以及预先溶解好的二氨基嘧啶氧化物、丙二醇，搅拌70-80转/分，搅拌10-15分钟，直至搅拌均匀；
步骤五：降温至50-55℃，加入预先溶解好的PEG-40氢化蓖麻油、生育酚(维生素E)、甘油辛酸酯、乳香(BOSWELLIA CARTERII)油和薰衣草(LAVANDULA ANGUSTIFOLIA)油，搅拌70-80转/分,搅拌10-15分钟，直至分散均匀
步骤六：降温至40-45℃，加入辛酰羟肟酸、1,2-己二醇和1,3-丙二醇、丁二醇、马齿苋(PORTULACA OLERACEA)提取物、葡糖酸锌、鳢肠(ECLIPTA PROSTRATA)提取物、丙二醇、苯氧乙醇、乙基己基甘油、羟丙基四氢吡喃三醇、二甲砜、当归(ANGELICA POLYMORPHASINENSIS)根提取物、何首乌(POLYGONUM MULTIFLORUM)根提取物、人参(PANAX GINSENG)根提取物、银杏(GINKGO BILOBA)叶提取物、多花黄精(POLYGONATUM MULTIFLORUM)根茎/根提取物、熟地黄(REHMANNIA GLUTINOSA)提取物、红花(CARTHAMUS TINCTORIUS)花提取物、杜仲(EUCOMMIA ULMOIDES)叶提取物、葡糖酸铜、葡糖酸亚铁，搅拌70-80转/分,搅拌10-15分钟，直至分散均匀；
步骤七：低于35℃停止搅拌；
步骤八：检验，出料；
步骤九：半成品检验；
步骤十：检验合格后，灌装；
步骤十一：包装；
步骤十二：成品检验，合格品入库。
所述肌酸的生理功能主要是参与生物体内ATP的转化，满足人体在运动时对高能量对需要，是常用对营养剂。
所述薰衣草油用于促进套膜蛋白、紧密连接蛋白的形成，提高皮肤的屏障功能，结合其抗氧化性，可用作抗衰剂；
所述乳香油可对过氧化酶激活受体有很好对活化作用，在皮肤损伤愈合过程中起着重要作用，有很好对抗炎性，对半胱天冬蛋白酶对活化有促进作用，可以一场细胞寿命，具有抗衰作用；同时可以促进毛发对生长，是不错对毛发生长剂。
所述羟丙基四氢吡喃三醇又名玻色因、Pro-xylane，有广泛对生物活性，可以刺激黏多糖(GAGs)对合成，促进生产透明质酸和胶原蛋白，它还可以改变真皮和表皮间对黏合度，通过诱导真皮和表皮结构成分对合成，促进受损组织再生，帮助维持真皮弹性，预防皮肤老化，达到抗衰老的作用。
所述银杏叶提取物用于对毛发乳头细胞有很好对增殖作用，表明有活血对功能，因此是很好对生发剂；
所述杜仲提取物可对酪氨酸酶有很好对活化作用，可明显增强黑色素细胞对活性，同时对外毛根鞘细胞有增殖作用和对5σ-还原酶的抑制，对因雄性激素偏高引起对脱发有很好的防治作用，可在脱发防治、生发类产品中使用，以减少白发或灰发的生成。还可以防治红血丝，也能作减肥剂；
所述何首乌根提取物为蓼科植物何首乌的干燥块根，主要功能成为是卵磷脂，大黄素，大黄酸和其他成分。主要作用：抗衰老作用、对免疫系统的影响、降血脂及抗动脉粥样硬化作用、心肌保护作用、保肝作用、神经保护作用、抗菌作用。可增强SOD活性，何首乌因其使头发黑亮的能力而被作为化妆品通过口服或外用而得到广泛应用。
所述鳢肠提取物是从鳢肠中提取，俗名旱莲草，具有凉血止血，滋补肝肾，清热解毒的功能。又叫墨旱莲，用于牙齿松动、须发早白、眩晕耳鸣、腰膝酸软、阴虚血热、吐血、等出血性症状。
所述三肽-1铜又名三胜铜肽，蓝铜胜肽。铜肽及其铜复合物可以作为组织重塑对激活剂和氧化剂，其也是一个承载类肽，可以促进伤疤外部大量胶原蛋白集聚物对降解，有助于促进皮肤正常胶原蛋白对合成及弹力蛋白、蛋白聚糖和葡糖胺聚糖对生成，具有抗炎抗氧化对作用。
所述腺苷为细胞生物学名词，是指由腺嘌呤的N-9与D-核糖的C-1通过β糖苷键连接而成的化合物，其磷酸酯为腺苷酸，腺苷是一种遍布人体细胞的内源性核苷，可直接进入心肌经磷酸化生成腺苷酸，参与心肌能量代谢，同时还参与扩张冠脉血管，增加血流量。
所述二氨基嘧啶氧化物，英文名：Kopyrrol，中译名：可比落；下文简称Kopyrrol或可比落，该成分经过核糖核酸临床测试表现数据为13.5％，位于目前世界防脱原料库有效指数值最高，并且零酒精。因高水溶性结构，适用于添加在洗护全品类中，可做发胶、发水、发乳、护发素、头皮液及头发喷雾等，该成分创新及临床验证100％水溶无酒精的头发生长促进剂。
本发明可改善脂溢性脱发、产后脱发、等病理性脱发以及病理性白发，有促进毛发生长和促进毛发健康的作用。
注意事项
仅限外用，禁止口服，置放于婴幼儿触及不到的地方；
头皮部位有溃烂伤口者慎用；本品同专业技师操作使用，效果更佳；
敏感性皮肤及对本品中成分过敏者慎用，如有不良反应请即刻停止使用；
使用过程中尽量避免熬夜、饮食辛辣、抽烟、喝酒以及保持良好心态；
对于不同年龄不同发质人群，改善有所不同；
使用期间无需特别忌口，保持心情乐观，调节好生活规律
使用方法
头发洗后用吹风机吹至半干状态；
取本品10ml-20ml，根据专业技师要求涂抹，并按摩头皮至本品吸收；
护理后无需再次清洗头发，使营业成分得以保留，将头发梳理成型，使毛发自然风干。
临床案例一：
基础资料：唐先生，男性、40岁；
生活习惯：不吸烟不喝酒，工作较为繁忙；
头皮情况：脂溢性脱发，发丝细，发色浅；
使用情况：
4月29日开始使用，每周三次，每次15ml，碰洒发根，按摩吸收，配合红光固发一起使用；
6月28日复检，头顶发丝密度明显增加，右鬓角密度增加，发丝增粗颜色加深；
9月1日二次复检，头顶发丝可以基本遮盖头顶皮肤，右鬓角头发粗度增加，头发生长周期拉长。
临床案例二
基础信息：乐先生，男性，23岁；
生活习惯：不吸烟不喝酒，工作稳定；
头皮情况：脂溢性脱发，头皮油脂分泌过剩，前额发际线退换；
使用情况：
8月23日开始疗程，每周三次，每次配合雪松焕发、积雪草精华、红光固发一起使用；
10月12日复测，头顶头发密度明显增加，鬓角发丝增粗增密，效果明显。
尽管参照前述实施例对本发明进行了详细的说明，对于本领域的技术人员来说，其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分技术特征进行等同替换，凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (2)
1.一种薰衣草乳香黑曜精华液配方及其制备方法，其特征在于：由以下原料配比组成：水10-30份、丙二醇5-8份、乙醇4-8份、丁二醇3-7份、甘油2-4份、乙氧基二甘醇2-7份、肌酸1-2份、PEG-40氢化蓖麻油0.5-2份、1,3-丙二醇2-5份、乳香(BOSWELLIA CARTERII)油3-7份、薰衣草(LAVANDULA ANGUSTIFOLIA)油3-6份、1,2-己二醇2-7份、二氨基嘧啶氧化物1-3份、葡糖酸锌0.5-0.8份、葡糖酸钙0.1-0.3份、葡糖酸铜0.2-0.4份、葡糖酸亚铁0.3-0.6份、羟丙基四氢吡喃三醇2-4份、腺苷3-6份、银杏(GINKGO BILOBA)叶提取物1-3份、甘油辛酸酯2-3份、生育酚(维生素E)1-4份、多花黄精(POLYGONATUM MULTIFLORUM)根茎/根提取物2-5份、熟地黄(REHMANNIA GLUTINOSA)提取物2-5份、人参(PANAX GINSENG)根提取物6-7份、杜仲(EUCOMMIA ULMOIDES)提取物5-8份、何首乌(POLYGONUM MULTIFLORUM)根提取物3-6份、马齿苋(PORTULACA OLERACEA)提取物4-8份、当归(ANGELICA POLYMORPHA SINENSIS)根提取物2-8份、鳢肠(ECLIPTA PROSTRATA)提取物4-8份、三肽-1铜1.5-2份、二甲砜3-7份、辛酰羟肟酸2-9份、苯氧乙醇1-5份和乙基己基甘油3-6份。
2.根据权利要求1所述的薰衣草乳香黑曜精华液配方及其制备方法，其特征在于：其制备方法步骤如下：
步骤一：前期处理：将PEG-40氢化蓖麻油、生育酚(维生素E)、甘油辛酸酯、乳香(BOSWELLIA CARTERII)油、辛酰羟肟酸、1,2-己二醇和1,3-丙二醇置于不锈钢容器中在水浴锅上加热至45-50℃，搅拌至溶解均匀备用；
步骤二：将二氨基嘧啶氧化物和丙二醇置于不锈钢容器中在水浴锅上加热至70-80℃，搅拌至溶解均匀备用；
步骤三：将水、乙醇和腺苷投入乳化锅，加热至65-70℃，搅拌70-80转/分,搅拌10-15分钟，直至分散均匀；
步骤四：乳化锅保温至65℃-70℃，加入甘油、肌酸、乙氧基二甘醇以及预先溶解好的二氨基嘧啶氧化物、丙二醇，搅拌70-80转/分，搅拌10-15分钟，直至搅拌均匀；
步骤五：降温至50-55℃，加入预先溶解好的PEG-40氢化蓖麻油、生育酚(维生素E)、甘油辛酸酯、乳香(BOSWELLIA CARTERII)油和薰衣草(LAVANDULA ANGUSTIFOLIA)油，搅拌70-80转/分,搅拌10-15分钟，直至分散均匀；
步骤六：降温至40-45℃，加入辛酰羟肟酸、1,2-己二醇和1,3-丙二醇、丁二醇、马齿苋(PORTULACA OLERACEA)提取物、葡糖酸锌、鳢肠(ECLIPTA PROSTRATA)提取物、丙二醇、苯氧乙醇、乙基己基甘油、羟丙基四氢吡喃三醇、二甲砜、当归(ANGELICA POLYMORPHASINENSIS)根提取物、何首乌(POLYGONUM MULTIFLORUM)根提取物、人参(PANAX GINSENG)根提取物、银杏(GINKGO BILOBA)叶提取物、多花黄精(POLYGONATUM MULTIFLORUM)根茎/根提取物、熟地黄(REHMANNIA GLUTINOSA)提取物、红花(CARTHAMUS TINCTORIUS)花提取物、杜仲(EUCOMMIA ULMOIDES)叶提取物、葡糖酸铜、葡糖酸亚铁，搅拌70-80转/分,搅拌10-15分钟，直至分散均匀；
步骤七：低于35℃停止搅拌；
步骤八：检验，出料；
步骤九：半成品检验；
步骤十：检验合格后，灌装；
步骤十一：包装；
步骤十二：成品检验，合格品入库。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111177428.XA CN113797142A (zh) | 2021-10-09 | 2021-10-09 | 一种薰衣草乳香黑曜精华液配方及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111177428.XA CN113797142A (zh) | 2021-10-09 | 2021-10-09 | 一种薰衣草乳香黑曜精华液配方及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113797142A true CN113797142A (zh) | 2021-12-17 |
Family
ID=78897489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111177428.XA Pending CN113797142A (zh) | 2021-10-09 | 2021-10-09 | 一种薰衣草乳香黑曜精华液配方及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113797142A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114732751A (zh) * | 2022-03-30 | 2022-07-12 | 彭氏(惠州)实业发展有限公司 | 一种含吡咯烷基二氨基嘧啶氧化物的防脱精华液 |
| CN114939095A (zh) * | 2022-06-22 | 2022-08-26 | 烟台新时代健康产业日化有限公司 | 一种控油防脱组合物及其制备方法以及护发喷雾、洗发水 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130030032A (ko) * | 2011-09-16 | 2013-03-26 | 한국콜마주식회사 | 허브 추출물을 포함하는 화장료 조성물 |
| CN107260627A (zh) * | 2017-06-05 | 2017-10-20 | 江门市蓬江区海豚水族有限公司 | 一种育发黑发精华液及其制备方法 |
| CN108992385A (zh) * | 2018-08-27 | 2018-12-14 | 天津市康婷生物工程有限公司 | 一种毛囊修复育发精华液 |
-
2021
- 2021-10-09 CN CN202111177428.XA patent/CN113797142A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130030032A (ko) * | 2011-09-16 | 2013-03-26 | 한국콜마주식회사 | 허브 추출물을 포함하는 화장료 조성물 |
| CN107260627A (zh) * | 2017-06-05 | 2017-10-20 | 江门市蓬江区海豚水族有限公司 | 一种育发黑发精华液及其制备方法 |
| CN108992385A (zh) * | 2018-08-27 | 2018-12-14 | 天津市康婷生物工程有限公司 | 一种毛囊修复育发精华液 |
Non-Patent Citations (1)
| Title |
|---|
| 上海塔丝密生物科技有限公司: "《国产普通化妆品备案信息》", 22 December 2020 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114732751A (zh) * | 2022-03-30 | 2022-07-12 | 彭氏(惠州)实业发展有限公司 | 一种含吡咯烷基二氨基嘧啶氧化物的防脱精华液 |
| CN114939095A (zh) * | 2022-06-22 | 2022-08-26 | 烟台新时代健康产业日化有限公司 | 一种控油防脱组合物及其制备方法以及护发喷雾、洗发水 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100761660B1 (ko) | 모발 성장 촉진 조성물 | |
| CN113797142A (zh) | 一种薰衣草乳香黑曜精华液配方及其制备方法 | |
| CN111803426A (zh) | 防脱固发营养液及制备方法 | |
| JPH06506668A (ja) | 痩身剤組成物における成長因子の使用 | |
| CN110123683A (zh) | 复方天然小分子植物提取物防脱生发组方及其产品 | |
| CN112870333A (zh) | 一种改善人脱发生发的组合物、制剂及制备方法和应用 | |
| CN110368397A (zh) | 一种防止脱发促进毛发生长的外用组合物及其制备方法 | |
| CN114432198B (zh) | 一种健发精华液及其使用方法 | |
| EP0719538B1 (en) | Skin external agent | |
| CN102908285A (zh) | 一种纯天然蜂王浆增白祛斑花粉膏及其生产方法 | |
| CN109288753A (zh) | 一种美白淡斑霜及其制备方法 | |
| KR102369387B1 (ko) | 탈모방지 및 발모촉진용 화장료 조성물 | |
| CN109512744A (zh) | 一种睫毛生长液及其制备方法 | |
| CN113876653A (zh) | 一种舒缓精华及其制备方法 | |
| CN106937957B (zh) | 一种用于治疗雄激素性脱发的组合物及其洗发液 | |
| KR20130038925A (ko) | 헤스페레틴의 신규 용도 | |
| US5637606A (en) | Hair grower based on allantoin or derivatives thereof | |
| CN107303254A (zh) | 一种生物素防脱营养液 | |
| CN107625956B (zh) | 一种木瓜蛋白酶组合物及其制备方法和应用 | |
| CN113633585B (zh) | 具有防脱发、生发及黑发功效的外用护发组合物、制剂及其制备方法 | |
| JP3357746B2 (ja) | 育毛剤 | |
| CN113069390A (zh) | 一种防脱生发水及其制备方法 | |
| CN114848558B (zh) | 一种防脱生发、白发转黑发的生发乌发液及其制备方法 | |
| CN113768803B (zh) | 一种防脱发去屑喷剂的组合物及制备方法 | |
| CN114948940B (zh) | 一种具有乌发健发功能的天然产物单体组合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211217 |
|
| WD01 | Invention patent application deemed withdrawn after publication |